Breaking barriers: the emerging promise of CAR-T cell therapy in solid tumors
Yongzhan Nie
Abstract
Abstract Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated significant clinical potential in solid tumors, including glioblastoma, gliomas and gastrointestinal cancers, extending its success from hematological malignancies to solid tumors, and revolutionizing cancer immunotherapy. Although response rates in the majority of solid tumors have been limited, promising results are emerging. Identifying potential factors that might hinder the clinical efficacy of CAR-T cell therapy in solid tumors and learning from successful trials are crucial for improving efficacy and facilitating its clinical application.
Topics & Concepts
MedicineSolid tumorClinical trialCancer researchCancer therapyCancerAntibody therapyCell therapyChimeric antigen receptorImmunotherapyOncologyRadiation therapyTargeted therapyCellImmune systemImmunologyTumor cellsSolid organInternal medicineChemotherapyCancer cellGastrointestinal cancerClinical PracticeAntigenSystemic therapyCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies ResearchVirus-based gene therapy research